Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6MHP Vaccine with BRAF and MEK Inhibitors in Melanoma
NCT02382549Phase 1Terminated
- Start
- Apr 2016
- Primary completion
- Feb 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melanoma helper peptide vaccine in melanoma. Primary endpoints: Adverse event profile for the combination of BRAFi, MEKi, and 6MHP and CD4+ T cell responses in the blood. Started Apr 2016; status: terminated.
02
Drugs
melanoma helper peptide vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02382549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382549.